BusinessOncoMed Initiates Enrollment of Phase 1b Clinical Trial of Anti-DLL4/VEGF Bispecific Antibody as Second-line Treatment for Metastatic Colorectal Cancer PatientsBy Nasdaq OMXJan 4, 2017, 1:32 PM UTC
BusinessOncoMed Presents Initial First-in-Human Data for Anti-DLL4/VEGF Bispecific and Anti-RSPO3 at the 28th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics SymposiumBy Nasdaq OMXNov 29, 2016, 1:31 PM UTC
